Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.

Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, Hu Y, Fabre C, Minami J, Ohguchi H, Kiziltepe T, Ikeda H, Kawano Y, French M, Blumenthal M, Tam V, Kertesz NL, Malyankar UM, Hokenson M, Pham T, Zeng Q, Patterson JB, Richardson PG, Munshi NC, Anderson KC.

Blood. 2012 Jun 14;119(24):5772-81. doi: 10.1182/blood-2011-07-366633. Epub 2012 Apr 26.

2.

A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.

Rastelli L, Valentino ML, Minderman MC, Landin J, Malyankar UM, Lescoe MK, Kitson R, Brunson K, Souan L, Forenza S, Goldfarb RH, Rabbani SA.

Int J Oncol. 2011 Aug;39(2):401-8. doi: 10.3892/ijo.2011.1040. Epub 2011 May 11.

PMID:
21567086
3.

Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease.

Volkmann K, Lucas JL, Vuga D, Wang X, Brumm D, Stiles C, Kriebel D, Der-Sarkissian A, Krishnan K, Schweitzer C, Liu Z, Malyankar UM, Chiovitti D, Canny M, Durocher D, Sicheri F, Patterson JB.

J Biol Chem. 2011 Apr 8;286(14):12743-55. doi: 10.1074/jbc.M110.199737. Epub 2011 Feb 8.

4.

Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination.

Smith KA, Qiu Z, Wong R, Tam VL, Tam BL, Joea DK, Quach A, Liu X, Pold M, Malyankar UM, Bot A.

Cancer Gene Ther. 2011 Jan;18(1):63-76. doi: 10.1038/cgt.2010.45. Epub 2010 Aug 20.

PMID:
20725097
5.

Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.

Smith KA, Meisenburg BL, Tam VL, Pagarigan RR, Wong R, Joea DK, Lantzy L, Carrillo MA, Gross TM, Malyankar UM, Chiang CS, Da Silva DM, Kündig TM, Kast WM, Qiu Z, Bot A.

Clin Cancer Res. 2009 Oct 1;15(19):6167-76. doi: 10.1158/1078-0432.CCR-09-0645. Epub 2009 Sep 29.

6.

Tumor-associated antigens and biomarkers in cancer and immune therapy.

Malyankar UM.

Int Rev Immunol. 2007 May-Aug;26(3-4):223-47. Review.

PMID:
17558745
7.

Genome-scale analysis of lung cancer progression.

Malyankar UM, MacDougall JR.

Am J Pharmacogenomics. 2004;4(3):169-76. Review.

PMID:
15174898
8.

Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells.

Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM.

J Biol Chem. 2000 Jul 14;275(28):20959-62.

9.

Upstream stimulatory factor 1 regulates osteopontin expression in smooth muscle cells.

Malyankar UM, Hanson R, Schwartz SM, Ridall AL, Giachelli CM.

Exp Cell Res. 1999 Aug 1;250(2):535-47.

PMID:
10413606
10.

Osteopontin regulation in cultured rat renal epithelial cells.

Malyankar UM, Almeida M, Johnson RJ, Pichler RH, Giachelli CM.

Kidney Int. 1997 Jun;51(6):1766-73.

13.

Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions.

Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM.

Pharmacol Ther. 1993 Sep;59(3):329-41. Review.

PMID:
8309995
14.

Role of host factors in the regulation of the enterotoxin B gene.

Compagnone-Post P, Malyankar U, Khan SA.

J Bacteriol. 1991 Mar;173(5):1827-30.

Supplemental Content

Loading ...
Support Center